非小细胞肺癌热点靶向药物及耐药机制的研究进展  

Advanced research of hot targeted drugs and drug resistance in non-small cell lung cancer

作　　者：孔珊珊 吴春娇[2] 林玉梅[3] 李军[3] 朱镇星[3] Kong Shanshan;Wu Chunjiao;Lin Yumei;Li Jun;Zhu Zhenxing(Department of Medical Oncology,Jilin Central Hospital,Jilin Jilin 132000,China;Department of Medical Oncology,Jilin Cancer Hospital,Jilin Changchun 130012,China;Department of Internal Medicine of Hematology Oncology,China-Japan Union Hospital of Jilin University,Jilin Changchun 130033,China.)

机构地区：[1]吉林市中心医院肿瘤内科,吉林吉林132000 [2]吉林省肿瘤医院肿瘤内科,吉林长春130012 [3]吉林大学中日联谊医院血液肿瘤内科,吉林长春130033

出　　处：《现代肿瘤医学》2018年第21期3523-3526,共4页Journal of Modern Oncology

摘　　要：非小细胞肺癌(NSCLC)已进入分子分型时代,对驱动基因及靶向用药的探索不断成熟。本文从肺癌常见驱动基因(以EGFR、ALK为主)靶向药物最新研究进展和耐药机制作以综述,以期为非小细胞肺癌患者在临床靶向用药方案选择上提供更好的参考。With the non-small cell lung cancer（NSCLC） has entered the molecular typing era,the driving gene and targeted drug are explored mature.We summarizes the latest research progress of the common driver genes and resistance mechanism of lung cancer （mainly EGFR and ALK） in order to provide a better reference for the selection of clinical targeted drugs in patients with non-small cell lung cancer.

关 键 词：非小细胞肺癌 常见驱动基因 靶向药物 

分 类 号：R734.2[医药卫生—肿瘤]